Trial Profile
Safety and tolerability of GS-9256 in treatment-naive patients with chronic genotype 1 hepatitis C virus infection: A randomised, double-blind, dose-escalation study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Jan 2018
Price :
$35
*
At a glance
- Drugs GS 9256 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- 05 Nov 2010 New trial record.